Seer will remain an independent public company after its board’s Special Committee unanimously rejected two unsolicited, non-binding proposals to acquire the company. The committee said that, after a three-month review of the offers and other strategic alternatives, it concluded a sale at this time would undervalue Seer and its future prospects.
The rejected proposals came from investor Bradley L. Radoff and Michael Torok, together with affiliates, and separately from Seer Chair and Chief Executive Omid Farokhzad.
Key details
- Radoff-Torok proposal: Submitted July 28, it offered $2.55 per share in cash plus a contingent value right. The proposal covered all outstanding shares of Seer’s Class A common stock.
- Farokhzad proposal: Submitted the following day, it offered $2.45 per share in cash plus two separate contingent value rights, also for all outstanding Class A shares.
- No sale was agreed: Both proposals were non-binding and have now been rejected. The announcement does not provide the terms of the contingent value rights.
- Review process: Over roughly three months, the Special Committee evaluated the proposals and other strategic alternatives, including possible interest from other potential transaction counterparties. Its two independent directors, Meeta Gulyani and Nicolas Roelofs, said the review was focused on shareholder value.
- Seer’s stated rationale: The committee said the proposals did not reflect the company’s intrinsic value. It pointed to Seer’s position in large-scale, unbiased proteomics and the opportunity it sees as demand grows alongside AI-driven biology.
What changes for investors
There is no announced acquisition or change in control: Seer says it will remain an independent public company. The decision leaves the company pursuing its existing business rather than accepting either offer. The committee’s view that Seer’s prospects justify a higher value is the company’s assessment, not a guaranteed outcome.